These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 31504596

  • 1. Prostate-Specific Antigen Levels During Testosterone Treatment of Hypogonadal Older Men: Data from a Controlled Trial.
    Cunningham GR, Ellenberg SS, Bhasin S, Matsumoto AM, Parsons JK, Preston P, Cauley JA, Gill TM, Swerdloff RS, Wang C, Ensrud KE, Lewis CE, Pahor M, Crandall JP, Molitch ME, Cifelli D, Basaria S, Diem SJ, Stephens-Shields AJ, Hou X, Snyder PJ.
    J Clin Endocrinol Metab; 2019 Dec 01; 104(12):6238-6246. PubMed ID: 31504596
    [Abstract] [Full Text] [Related]

  • 2. Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months.
    Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG.
    J Sex Med; 2014 Nov 01; 11(11):2818-25. PubMed ID: 25131184
    [Abstract] [Full Text] [Related]

  • 3. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED, Lamb DJ, Khera M, Murthy L, Lipshultz LI.
    Int J Impot Res; 2008 Nov 01; 20(6):561-5. PubMed ID: 18843272
    [Abstract] [Full Text] [Related]

  • 4. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
    Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM.
    J Urol; 2011 Sep 01; 186(3):1005-11. PubMed ID: 21788049
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A, Rhoden EL.
    Urology; 2006 Dec 01; 68(6):1263-7. PubMed ID: 17169647
    [Abstract] [Full Text] [Related]

  • 6. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP, Gardette J, Rollet J, Legros JJ.
    BJU Int; 2013 May 01; 111(6):880-90. PubMed ID: 23294726
    [Abstract] [Full Text] [Related]

  • 7. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL, Morgentaler A.
    J Urol; 2003 Dec 01; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM, Simhan J, Carson CC.
    BJU Int; 2009 May 01; 103(9):1179-83. PubMed ID: 19154450
    [Abstract] [Full Text] [Related]

  • 9. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement.
    Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD.
    J Androl; 2002 May 01; 23(6):922-6. PubMed ID: 12399540
    [Abstract] [Full Text] [Related]

  • 10. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.
    J Urol; 2011 Jul 01; 186(1):191-7. PubMed ID: 21575967
    [Abstract] [Full Text] [Related]

  • 11. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS.
    JAMA; 2006 Nov 15; 296(19):2351-61. PubMed ID: 17105798
    [Abstract] [Full Text] [Related]

  • 12. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL, Morgentaler A.
    Int J Impot Res; 2006 Nov 15; 18(2):201-5. PubMed ID: 16177827
    [Abstract] [Full Text] [Related]

  • 13. Racial differences in hypogonadal improvement and prostate-specific antigen levels in hypogonadal men treated with testosterone replacement therapy.
    Coward RM, Simhan J, Carson CC.
    Int Braz J Urol; 2010 Nov 15; 36(6):700-7; discussion 707-9. PubMed ID: 21176276
    [Abstract] [Full Text] [Related]

  • 14. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM, Behre HM, Roehrborn CG, Maggi M, Wu FC, Schröder FH, Jones TH, Porst H, Hackett G, Wheaton OA, Martin-Morales A, Meuleman E, Cunningham GR, Divan HA, Rosen RC, RHYME Investigators.
    BJU Int; 2017 Feb 15; 119(2):216-224. PubMed ID: 27409523
    [Abstract] [Full Text] [Related]

  • 15. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.
    Guay AT, Perez JB, Fitaihi WA, Vereb M.
    Endocr Pract; 2000 Feb 15; 6(2):132-8. PubMed ID: 11421528
    [Abstract] [Full Text] [Related]

  • 16. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M.
    Int J Impot Res; 2013 Jan 15; 25(1):24-8. PubMed ID: 22971614
    [Abstract] [Full Text] [Related]

  • 17. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
    Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, Miles BJ, Lipshultz LI, Khera M.
    J Urol; 2013 Aug 15; 190(2):639-44. PubMed ID: 23395803
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
    Gould DC, Feneley MR, Kirby RS.
    BJU Int; 2006 Jul 15; 98(1):1-4. PubMed ID: 16831134
    [Abstract] [Full Text] [Related]

  • 19. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
    Bhattacharya RK, Khera M, Blick G, Kushner H, Miner MM.
    Clin Interv Aging; 2012 Jul 15; 7():321-30. PubMed ID: 22956867
    [Abstract] [Full Text] [Related]

  • 20. The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction.
    Svetec DA, Canby ED, Thompson IM, Sabanegh ES.
    J Urol; 1997 Nov 15; 158(5):1775-7. PubMed ID: 9334599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.